{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:17:12Z","timestamp":1768472232815,"version":"3.49.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Danish National Mass Spectrometry Platform for Functional Proteomics","award":["5072-00007B"],"award-info":[{"award-number":["5072-00007B"]}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["23083"],"award-info":[{"award-number":["23083"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007432","name":"Shiraz Institute for Cancer research","doi-asserted-by":"crossref","award":["ICR-100-503"],"award-info":[{"award-number":["ICR-100-503"]}],"id":[{"id":"10.13039\/501100007432","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate and muscle-invasive bladder cancer (MIBC) has unfavorable outcomes in urothelial bladder cancer (UBC) patients. Complex UBC-related protein biomarkers for outcome prediction may provide a more efficient management approach with an improved clinical outcome. The aim of this study is to recognize tumor-associated proteins, which are differentially expressed in different stages of UBC patients compared non-cancerous tissues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The proteome of tissue samples of 42 UBC patients (NMIBC n\u2009=\u200925 and MIBC n\u2009=\u200917) was subjected to two-dimensional electrophoresis (2-DE) combined with Liquid chromatography\u2013mass spectrometry (LC\u2013MS) system to identify differentially expressed proteins. The intensity of protein spots was quantified and compared with Prodigy SameSpots software. Functional, pathway, and interaction analyses of identified proteins were performed using geneontology (GO), PANTHER, Reactome, Gene MANIA, and STRING databases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twelve proteins identified by LC-MS showed differential expression (over 1.5-fold, p\u2009&lt;\u20090.05) by LC-MS, including 9 up-regulated in NMIBC and 3 up-regulated in MIBC patients. Proteins involved in the detoxification of reactive oxygen species and cellular responses to oxidative stress showed the most significant changes in UBC patients. Additionally, the most potential functions related to these detected proteins were associated with peroxidase, oxidoreductase, and antioxidant activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We identified several alterations in protein expression involved in canonical pathways which were correlated with the clinical outcomes suggested might be useful as promising biomarkers for early detection, monitoring, and prognosis of UBC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12014-023-09419-8","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T08:01:56Z","timestamp":1690444916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity"],"prefix":"10.1186","volume":"20","author":[{"given":"Samira","family":"Tabaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Haghshenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ariafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kambiz","family":"Gilany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Stensballe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Farjadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-3375","authenticated-orcid":false,"given":"Abbas","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"9419_CR1","doi-asserted-by":"crossref","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP et al. Epidemiology, screening, and Prevention of bladder Cancer. Eur Urol Oncol. 2022.","DOI":"10.1016\/j.euo.2022.10.003"},{"issue":"4","key":"9419_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/ijerph15040569","volume":"15","author":"FHM Van Osch","year":"2018","unstructured":"Van Osch FHM, Jochems SHJ, Wesselius A, Van Schooten FJ, Bryan RT, Zeegers MP. A stratified meta-analysis of the association between exposure to environmental tobacco smoke during childhood and adulthood and urothelial bladder cancer risk. Int J Environ Res Public Health. 2018;15(4):569.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"9419_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23\u201334.","journal-title":"Nat Rev Urol"},{"key":"9419_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2020.00102","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Yu W, Yang X, Wu C, Cheng F. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol. 2020;10:102.","journal-title":"Front Oncol"},{"issue":"13","key":"9419_CR5","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3390\/cancers14133181","volume":"14","author":"X Hu","year":"2022","unstructured":"Hu X, Li G, Wu S. Advances in diagnosis and therapy for bladder cancer. Cancers (Basel). 2022;14(13):3181.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"9419_CR6","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.3390\/ijms23158597","volume":"23","author":"M Matuszczak","year":"2022","unstructured":"Matuszczak M, Kilja\u0144czyk A, Salagierski M. A liquid biopsy in bladder Cancer\u2014the current Landscape in urinary biomarkers. Int J Mol Sci. 2022;23(15):8597.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9419_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-09733-8","volume":"22","author":"S Jeong","year":"2022","unstructured":"Jeong S, Han JH, Jeong CW, Kim HH, Kwak C, Yuk HD, et al. Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor. BMC Cancer. 2022;22(1):1\u20136.","journal-title":"BMC Cancer"},{"issue":"1","key":"9419_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cancers13010048","volume":"13","author":"C Tay","year":"2020","unstructured":"Tay C, Qian Y, Sakaguchi S. Hyper-progressive disease: the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy. Cancers (Basel). 2020;13(1):48.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"9419_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/BLC-190238","volume":"5","author":"WP Tan","year":"2019","unstructured":"Tan WP, Tan WS, Inman BA. PD-L1\/PD-1 biomarker for metastatic urothelial cancer that progress post-platinum therapy: a systematic review and meta-analysis. Bl Cancer. 2019;5(3):211\u201323.","journal-title":"Bl Cancer"},{"issue":"1","key":"9419_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","volume":"37","author":"F Soria","year":"2019","unstructured":"Soria F, Krabbe LM, Todenh\u00f6fer T, Dobruch J, Mitra AP, Inman BA, et al. Molecular markers in bladder cancer. World J Urol. 2019;37(1):31\u201340.","journal-title":"World J Urol"},{"key":"9419_CR11","doi-asserted-by":"crossref","unstructured":"Tabaei S, Haghshenas MR, Webster TJ, Ghaderi A. Proteomic strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources. Anal Biochem [Internet]. 2023;115074. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0003269723000398.","DOI":"10.1016\/j.ab.2023.115074"},{"issue":"3","key":"9419_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/life12030395","volume":"12","author":"JH Ahn","year":"2022","unstructured":"Ahn JH, Kang CK, Kim EM, Kim AR, Kim A. Proteomics for early detection of non-muscle-invasive bladder Cancer: clinically useful urine protein biomarkers. Life. 2022;12(3):395.","journal-title":"Life"},{"issue":"12","key":"9419_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-017-0748-x","volume":"18","author":"A Leiblich","year":"2017","unstructured":"Leiblich A. Recent developments in the search for urinary biomarkers in bladder cancer. Curr Urol Rep. 2017;18(12):1\u20136.","journal-title":"Curr Urol Rep"},{"key":"9419_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1590\/s1677-5538.ibju.2021.99.02","volume":"47","author":"JL Wilson Jr","year":"2021","unstructured":"Wilson JL Jr, Antoniassi MP, Lopes PI, Azevedo H. Proteomic research and diagnosis in bladder cancer: state of the art review. Int braz j urol. 2021;47:503\u201314.","journal-title":"Int braz j urol"},{"key":"9419_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3389\/fonc.2020.00957","volume":"10","author":"Y Jian","year":"2020","unstructured":"Jian Y, Xu Z, Xu C, Zhang L, Sun X, Yang D, et al. The roles of glycans in bladder cancer. Front Oncol. 2020;10:957.","journal-title":"Front Oncol"},{"issue":"9","key":"9419_CR16","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1074\/mcp.M115.051524","volume":"14","author":"CL Chen","year":"2015","unstructured":"Chen CL, Chung T, Wu CC, Ng KF, Yu JS, Tsai CH, et al. Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder cancer. Mol Cell proteomics. 2015;14(9):2466\u201378.","journal-title":"Mol Cell proteomics"},{"issue":"41","key":"9419_CR17","doi-asserted-by":"publisher","first-page":"69435","DOI":"10.18632\/oncotarget.17279","volume":"8","author":"A Latosinska","year":"2017","unstructured":"Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, et al. Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention. Oncotarget. 2017;8(41):69435.","journal-title":"Oncotarget"},{"key":"9419_CR18","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. John Wiley & Sons; 2017.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"9419_CR19","doi-asserted-by":"crossref","unstructured":"Kruger NJ. The Bradford method for protein quantitation. protein Protoc Handb. 2009;17\u201324.","DOI":"10.1007\/978-1-59745-198-7_4"},{"key":"9419_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijid.2020.02.026","volume":"96","author":"MG Snips\u00f8yr","year":"2020","unstructured":"Snips\u00f8yr MG, Wiggers H, Ludvigsen M, Stensballe A, Vorum H, Poulsen SH, et al. Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis. Int J Infect Dis. 2020;96:73\u201381.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"9419_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259\u201370.","journal-title":"Nat Rev Urol"},{"key":"9419_CR22","doi-asserted-by":"publisher","first-page":"108365","DOI":"10.1016\/j.mrrev.2021.108365","volume":"787","author":"AW Caliri","year":"2021","unstructured":"Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Mutat Res. 2021;787:108365.","journal-title":"Mutat Res Mutat Res"},{"issue":"11","key":"9419_CR23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2967\/jnumed.120.256974","volume":"62","author":"HE Greenwood","year":"2021","unstructured":"Greenwood HE, Witney TH. Latest advances in imaging oxidative stress in cancer. J Nucl Med. 2021;62(11):1506\u201310.","journal-title":"J Nucl Med"},{"key":"9419_CR24","doi-asserted-by":"publisher","first-page":"101959","DOI":"10.1016\/j.redox.2021.101959","volume":"42","author":"J Bolduc","year":"2021","unstructured":"Bolduc J, Koruza K, Luo T, Pueyo JM, Vo TN, Ezeri\u0146a D, et al. Peroxiredoxins wear many hats: factors that fashion their peroxide sensing personalities. Redox Biol. 2021;42:101959.","journal-title":"Redox Biol"},{"key":"9419_CR25","doi-asserted-by":"publisher","first-page":"9685","DOI":"10.2147\/CMAR.S229389","volume":"11","author":"G Wang","year":"2019","unstructured":"Wang G, Zhong WC, Bi YH, Tao SY, Zhu H, Zhu HX, et al. The prognosis of peroxiredoxin family in breast cancer. Cancer Manag Res. 2019;11:9685.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"9419_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jcmm.12955","volume":"21","author":"C Ding","year":"2017","unstructured":"Ding C, Fan X, Wu G. Peroxiredoxin 1\u2013an antioxidant enzyme in cancer. J Cell Mol Med. 2017;21(1):193\u2013202.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"9419_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ijms21031106","volume":"21","author":"SV Hindupur","year":"2020","unstructured":"Hindupur SV, Schmid SC, Koch JA, Youssef A, Baur EM, Wang D, et al. STAT3\/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. Int J Mol Sci. 2020;21(3):1106.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"9419_CR28","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.7150\/jca.69811","volume":"13","author":"N Kumari","year":"2022","unstructured":"Kumari N, Vasudeva P, Tanwar P, Hussain S, Kumar A, Agrawal U. Peroxiredoxins-urinary surveillance biomarkers in Urothelial Cancer. J Cancer. 2022;13(9):2751.","journal-title":"J Cancer"},{"issue":"1","key":"9419_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1021\/pr900811x","volume":"9","author":"K Chung","year":"2010","unstructured":"Chung K, Lee DH, Kim Y, Kim T, heon, Huh JH, Chung S, geun, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010;9(1):451\u20137.","journal-title":"J Proteome Res"},{"issue":"21","key":"9419_CR30","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.7150\/jca.26041","volume":"9","author":"Y He","year":"2018","unstructured":"He Y, Xu W, Xiao Y, Pan L, Chen G, Tang Y, et al. Overexpression of peroxiredoxin 6 (PRDX6) promotes the aggressive phenotypes of esophageal squamous cell carcinoma. J Cancer. 2018;9(21):3939.","journal-title":"J Cancer"},{"issue":"9","key":"9419_CR31","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.7150\/jca.39892","volume":"11","author":"X Hu","year":"2020","unstructured":"Hu X. Overexpression and biological function of PRDX6 in human cervical cancer. J Cancer. 2020;11(9):2390.","journal-title":"J Cancer"},{"issue":"2","key":"9419_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/mco.2017.1129","volume":"6","author":"A Nicolussi","year":"2017","unstructured":"Nicolussi A, D\u2019inzeo S, Capalbo C, Giannini G, Coppa A. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017;6(2):139\u201353.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"9419_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02064-x","volume":"21","author":"L Gao","year":"2021","unstructured":"Gao L, Meng J, Yue C, Wu X, Su Q, Wu H, et al. Integrative analysis the characterization of peroxiredoxins in pan-cancer. Cancer Cell Int. 2021;21(1):1\u201317.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"9419_CR34","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.18632\/oncotarget.14801","volume":"8","author":"L Peng","year":"2017","unstructured":"Peng L, Wang R, Shang J, Xiong Y, Fu Z. Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients. Oncotarget. 2017;8(9):15057.","journal-title":"Oncotarget"},{"issue":"6","key":"9419_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03888-1","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Wei J, Zhang H, Zheng X, Zhou H, Luo Y, et al. PRDX2 promotes the proliferation of colorectal cancer cells by increasing the ubiquitinated degradation of p53. Cell Death Dis. 2021;12(6):1\u201310.","journal-title":"Cell Death Dis"},{"issue":"11","key":"9419_CR36","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1021\/pr100576x","volume":"9","author":"YT Chen","year":"2010","unstructured":"Chen YT, Chen CL, Chen HW, Chung T, Wu CC, Chen CD, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res. 2010;9(11):5803\u201315.","journal-title":"J Proteome Res"},{"key":"9419_CR37","doi-asserted-by":"crossref","unstructured":"Yang GJ, Tao F, Zhong HJ, Yang C, Chen J. Targeting PGAM1 in cancer: an emerging therapeutic opportunity. Eur J Med Chem. 2022;114798.","DOI":"10.1016\/j.ejmech.2022.114798"},{"key":"9419_CR38","doi-asserted-by":"crossref","unstructured":"Fareed MM, El-Esawi MA, El-Ballat EM, Batiha GES, Rauf A, El-Demerdash FM et al. In Silico Drug Screening Analysis against the Overexpression of PGAM1 Gene in Different Cancer Treatments. Biomed Res Int. 2021;2021.","DOI":"10.1155\/2021\/5515692"},{"issue":"6","key":"9419_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrurol.2015.100","volume":"12","author":"M Frantzi","year":"2015","unstructured":"Frantzi M, Latosinska A, Fl\u00fche L, Hupe MC, Critselis E, Kramer MW, et al. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015;12(6):317\u201330.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"9419_CR40","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3727\/096504018X15166223632406","volume":"26","author":"X Liu","year":"2018","unstructured":"Liu X, Tan X, Liu P, Wu Y, Qian S, Zhang X. Phosphoglycerate mutase 1 (PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of the PI3K\/Akt\/mTOR pathway. Oncol Res. 2018;26(7):1123.","journal-title":"Oncol Res"},{"key":"9419_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jprot.2015.11.027","volume":"132","author":"XC Peng","year":"2016","unstructured":"Peng XC, Gong FM, Chen Y, Qiu M, Cheng K, Tang J, et al. Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. J Proteom. 2016;132:85\u201392.","journal-title":"J Proteom"},{"issue":"6","key":"9419_CR42","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41418-017-0034-y","volume":"25","author":"Q Sun","year":"2018","unstructured":"Sun Q, Li S, Wang Y, Peng H, Zhang X, Zheng Y, et al. Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death Differ. 2018;25(6):1160\u201373.","journal-title":"Cell Death Differ"},{"issue":"733","key":"9419_CR43","doi-asserted-by":"publisher","first-page":"eabh3066","DOI":"10.1126\/scisignal.abh3066","volume":"15","author":"C Vasavda","year":"2022","unstructured":"Vasavda C, Semenza ER, Liew J, Kothari R, Dhindsa RS, Shanmukha S, et al. Biliverdin reductase bridges focal adhesion kinase to src to modulate synaptic signaling. Sci Signal. 2022;15(733):eabh3066.","journal-title":"Sci Signal"},{"key":"9419_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fphar.2015.00119","volume":"6","author":"PEM Gibbs","year":"2015","unstructured":"Gibbs PEM, Miralem T, Maines MD. Biliverdin reductase: a target for cancer therapy? Front Pharmacol. 2015;6:119.","journal-title":"Front Pharmacol"},{"issue":"5","key":"9419_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/carcin\/bgab015","volume":"42","author":"H Ramberg","year":"2021","unstructured":"Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, et al. Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis. 2021;42(5):685\u201393.","journal-title":"Carcinogenesis"},{"key":"9419_CR46","doi-asserted-by":"crossref","unstructured":"Wang F, Zhang C, Zhu X, Zhang D, Zhang Z, Ni S et al. Overexpression of GSTP1 promotes colorectal cancer cell proliferation, invasion and metastasis by up-regulating STAT3. 2021.","DOI":"10.21203\/rs.3.rs-315672\/v1"},{"issue":"12","key":"9419_CR47","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.3390\/diagnostics12123184","volume":"12","author":"I Vujicic","year":"2022","unstructured":"Vujicic I, Rusevski A, Stankov O, Popov Z, Dimovski A, Davalieva K. Potential role of seven proteomics tissue biomarkers for diagnosis and prognosis of prostate Cancer in urine. Diagnostics. 2022;12(12):3184.","journal-title":"Diagnostics"},{"issue":"5","key":"9419_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.chembiol.2016.03.017","volume":"23","author":"SM Louie","year":"2016","unstructured":"Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, et al. GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem Biol. 2016;23(5):567\u201378.","journal-title":"Cell Chem Biol"},{"key":"9419_CR49","doi-asserted-by":"crossref","unstructured":"Pljesa-Ercegovac M, Savic-Radojevic A, Dragicevic D, Mimic-Oka J, Matic M, Sasic T et al. Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways. Urologic oncology: seminars and original investigations. Elsevier; 2011. 70\u20137.","DOI":"10.1016\/j.urolonc.2008.10.019"},{"issue":"6","key":"9419_CR50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/acs.chemrestox.9b00069","volume":"32","author":"EG Stoddard","year":"2019","unstructured":"Stoddard EG, Killinger BJ, Nag SA, Martin J, Corley R, Smith JN, et al. Benzo [a] pyrene induction of glutathione S-transferases: an activity-based protein profiling investigation. Chem Res Toxicol. 2019;32(6):1259\u201367.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"9419_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6244-6","volume":"19","author":"N Albarakati","year":"2019","unstructured":"Albarakati N, Khayyat D, Dallol A, Al-Maghrabi J, Nedjadi T. The prognostic impact of GSTM1\/GSTP1 genetic variants in bladder cancer. BMC Cancer. 2019;19(1):1\u201311.","journal-title":"BMC Cancer"},{"issue":"2","key":"9419_CR52","doi-asserted-by":"publisher","first-page":"L328","DOI":"10.1152\/ajplung.00156.2016","volume":"311","author":"IE Kammerl","year":"2016","unstructured":"Kammerl IE, Meiners S. Proteasome function shapes innate and adaptive immune responses. Am J Physiol Cell Mol Physiol. 2016;311(2):L328\u201336.","journal-title":"Am J Physiol Cell Mol Physiol"},{"issue":"12","key":"9419_CR53","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/cells10123587","volume":"10","author":"SC Tripathi","year":"2021","unstructured":"Tripathi SC, Vedpathak D, Ostrin EJ. The functional and mechanistic roles of immunoproteasome subunits in cancer. Cells. 2021;10(12):3587.","journal-title":"Cells"},{"issue":"34","key":"9419_CR54","doi-asserted-by":"publisher","first-page":"13791","DOI":"10.1073\/pnas.1300013110","volume":"110","author":"D S\u00e1nchez-Mart\u00edn","year":"2013","unstructured":"S\u00e1nchez-Mart\u00edn D, Mart\u00ednez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Xim\u00e9nez-Emb\u00fan P, et al. Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proc Natl Acad Sci. 2013;110(34):13791\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"9419_CR55","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.7150\/jca.30612","volume":"10","author":"Q Wang","year":"2019","unstructured":"Wang Q, Pan F, Li S, Huang R, Wang X, Wang S, et al. The prognostic value of the proteasome activator subunit gene family in skin cutaneous melanoma. J Cancer. 2019;10(10):2205.","journal-title":"J Cancer"},{"issue":"18","key":"9419_CR56","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms20184507","volume":"20","author":"BJ Lang","year":"2019","unstructured":"Lang BJ, Guerrero-Gim\u00e9nez ME, Prince TL, Ackerman A, Bonorino C, Calderwood SK. Heat shock proteins are essential components in transformation and tumor progression: cancer cell intrinsic pathways and beyond. Int J Mol Sci. 2019;20(18):4507.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"9419_CR57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/his.13284","volume":"71","author":"P Wu","year":"2017","unstructured":"Wu P, Chang Y, Pan C. High expression of heat shock proteins and heat shock factor-1 distinguishes an aggressive subset of clear cell renal cell carcinoma. Histopathology. 2017;71(5):711\u20138.","journal-title":"Histopathology"},{"issue":"1","key":"9419_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13956-2","volume":"7","author":"B Sheng","year":"2017","unstructured":"Sheng B, Qi C, Liu B, Lin Y, Fu T, Zeng Q. Increased HSP27 correlates with malignant biological behavior of non-small cell lung cancer and predicts patient\u2019s survival. Sci Rep. 2017;7(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"1","key":"9419_CR59","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/cancers6010333","volume":"6","author":"AP Arrigo","year":"2014","unstructured":"Arrigo AP, Gibert B. HspB1, HspB5 and HspB4 in human cancers: potent oncogenic role of some of their client proteins. Cancers (Basel). 2014;6(1):333\u201365.","journal-title":"Cancers (Basel)"},{"issue":"56","key":"9419_CR60","doi-asserted-by":"publisher","first-page":"30731","DOI":"10.18632\/oncotarget.24578","volume":"9","author":"CH Tsai","year":"2018","unstructured":"Tsai CH, Chen YT, Chang YH, Hsueh C, Liu CY, Chang YS, et al. Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens. Oncotarget. 2018;9(56):30731.","journal-title":"Oncotarget"},{"issue":"13","key":"9419_CR61","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2174\/1389450118666170823121248","volume":"19","author":"J Saini","year":"2018","unstructured":"Saini J, Sharma PK. Clinical, prognostic and therapeutic significance of heat shock proteins in cancer. Curr Drug Targets. 2018;19(13):1478\u201390.","journal-title":"Curr Drug Targets"},{"key":"9419_CR62","doi-asserted-by":"publisher","first-page":"175883591984123","DOI":"10.1177\/1758835919841235","volume":"11","author":"L Zhaojie","year":"2019","unstructured":"Zhaojie L, Yuchen L, Miao C, Yacun C, Shayi W, Anbang H, et al. Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer. Ther Adv Med Oncol. 2019;11:1758835919841235.","journal-title":"Ther Adv Med Oncol"},{"issue":"02","key":"9419_CR63","first-page":"186","volume":"18","author":"S Bahrami","year":"2020","unstructured":"Bahrami S, Gheysarzadeh A, Sotoudeh M, Bandehpour M, Zali H, Hedayati M, et al. The Association between Gelsolin-like actin-capping protein (CapG) overexpression and bladder Cancer prognosis. Urol J. 2020;18(02):186\u201393.","journal-title":"Urol J"},{"issue":"1","key":"9419_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"NQ Liu","year":"2016","unstructured":"Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AMAC, Foekens R, Look MP, et al. Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. Sci Rep. 2016;6(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"7809","key":"9419_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434\u201343.","journal-title":"Nature"},{"key":"9419_CR66","doi-asserted-by":"crossref","unstructured":"Liu NQ, Stingl C, Look MP, Smid M, Braakman RBH, De Marchi T et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. JNCI J Natl Cancer Inst. 2014;106(2).","DOI":"10.1093\/jnci\/djt376"},{"key":"9419_CR67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.dib.2017.05.022","volume":"13","author":"D Zhou","year":"2017","unstructured":"Zhou D, Zhang L, Lin Q, Ren W, Xu G. Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer. Data Br. 2017;13:77\u201384.","journal-title":"Data Br"},{"issue":"1","key":"9419_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02402-z","volume":"22","author":"P Li","year":"2022","unstructured":"Li P, Li L, Li Z, Wang S, Li R, Zhao W, et al. Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway. Cancer Cell Int. 2022;22(1):1\u201319.","journal-title":"Cancer Cell Int"},{"key":"9419_CR69","doi-asserted-by":"crossref","unstructured":"Wu W, Jia G, Chen L, Liu H, Xia S. Analysis of the expression and prognostic value of annexin family proteins in bladder Cancer. Front Genet. 2021;12.","DOI":"10.3389\/fgene.2021.731625"},{"issue":"1","key":"9419_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15920-6","volume":"7","author":"G de Velasco","year":"2017","unstructured":"de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sep\u00falveda JM, et al. Urothelial cancer proteomics provides both prognostic and functional information. Sci Rep. 2017;7(1):1\u20138.","journal-title":"Sci Rep"},{"issue":"1","key":"9419_CR71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/00313020903434405","volume":"42","author":"CF Li","year":"2010","unstructured":"Li CF, Shen KH, Huang LC, Huang HY, Wang YH, Wu TF. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma. Pathology. 2010;42(1):43\u20139.","journal-title":"Pathology"},{"issue":"8","key":"9419_CR72","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41388-018-0510-y","volume":"38","author":"K Arima","year":"2019","unstructured":"Arima K, Ohmuraya M, Miyake K, Koiwa M, Uchihara T, Izumi D, et al. Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas. Oncogene. 2019;38(8):1211\u201324.","journal-title":"Oncogene"},{"issue":"8","key":"9419_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-00256-0","volume":"9","author":"SR Satapathy","year":"2020","unstructured":"Satapathy SR, Topi G, Osman J, Hellman K, Ek F, Olsson R, et al. Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition. Oncogenesis. 2020;9(8):1\u201316.","journal-title":"Oncogenesis"},{"key":"9419_CR74","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.2147\/CMAR.S245726","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Li J, Dong J, Zhang L, Liu D, He J, et al. 15-PGDH expression in gastric cancer: a potential role in anti-tumor immunity. Cancer Manag Res. 2020;12:7419.","journal-title":"Cancer Manag Res"},{"issue":"1\u20132","key":"9419_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jsbmb.2010.03.049","volume":"121","author":"M Thill","year":"2010","unstructured":"Thill M, Fischer D, Kelling K, Hoellen F, Dittmer C, Hornemann A, et al. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25 (OH2) D3) and prostaglandin E2 (PGE2) serum level in ovarian canc. J Steroid Biochem Mol Biol. 2010;121(1\u20132):387\u201390.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"9419_CR76","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/path.3956","volume":"226","author":"L Lehtinen","year":"2012","unstructured":"Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial\u2013mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol. 2012;226(4):674\u201386.","journal-title":"J Pathol"},{"issue":"3","key":"9419_CR77","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2353\/ajpath.2010.090875","volume":"176","author":"S Tseng-Rogenski","year":"2010","unstructured":"Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol. 2010;176(3):1462\u20138.","journal-title":"Am J Pathol"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-023-09419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-023-09419-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-023-09419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T08:02:25Z","timestamp":1690444945000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-023-09419-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["9419"],"URL":"https:\/\/doi.org\/10.1186\/s12014-023-09419-8","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants included in the study. All procedures for tissue sample collection have been ethically approved by the Ethics Committee of Shiraz University of Medical Sciences [IR.SUMS.REC.1400.369].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}